Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01065558 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of the D1 Dopamine Receptor Antagonist Ecopipam in Patients With Lesch-Nyhan Disease
A Phase 1 study of Lesch-Nyhan Disease, sponsored by Psyadon Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 2
- Study locations
NCT01065558 is a Phase 1 study of Lesch-Nyhan Disease that has completed, run by Psyadon Pharma. The registered enrollment target is 5 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT01065558, a Phase 1 study of Lesch-Nyhan Disease, has completed, sponsored by Psyadon Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine the effects of ecopipam in patients with Lesch-Nyhan Disease (LND). Ecopipam specifically blocks the actions of one chemical in the brain that helps nerves talk to one another; ecopipam does this by stopping the chemical (dopamine) from binding to one of its family of receptors (i.e, the D1 family). LND is a very rare genetic disease. The sponsor is doing this study to find out what side effects ecopipam causes in LND patients, and whether ecopipam may be able to relieve the self-injurious behaviors seen in these patients.
Conditions Studied
Interventions
- DRUG Ecopipam
Study Locations (2)
California
- University of California at San Diego - San Diego
Georgia
- Emory Univesity - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-02 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01065558
The ClinicalTrials.gov registry entry for NCT01065558 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Psyadon Pharma, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lesch-Nyhan Disease appearing as the primary indexed condition, and to 1 intervention - of which Ecopipam is the first listed.
NCT01065558 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Georgia.
Frequently Asked Questions
What is clinical trial NCT01065558 about?
NCT01065558 is a clinical study titled "Safety and Tolerability of the D1 Dopamine Receptor Antagonist Ecopipam in Patients With Lesch-Nyhan Disease". The purpose of this study is to determine the effects of ecopipam in patients with Lesch-Nyhan Disease (LND). Ecopipam specifically blocks the actions of one chemical in the brain that helps nerves talk to one another; ecopipam does this by stopping the chemical (dopamine) from binding to one of its...
What is the current status of trial NCT01065558?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2010-02. Estimated completion is 2011-06.
What conditions does trial NCT01065558 study?
This clinical trial studies the following conditions: Lesch-Nyhan Disease.
What interventions are being tested in trial NCT01065558?
The interventions under investigation include: Ecopipam (DRUG).
Who is sponsoring clinical trial NCT01065558?
This trial is sponsored by Psyadon Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01065558 being conducted?
This trial has 2 study locations across California, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.